Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

被引:5
|
作者
Holzhauer, Bjorn [1 ]
机构
[1] Novartis Pharma AG, Biostat Sci & Pharmacometr, Basel, Switzerland
来源
关键词
Bayesian model averaging; Rare events; Robust meta-analytic predictive prior; Safety meta-analysis; Shrinkage priors; ANALYTIC-PREDICTIVE PRIORS; INFORMATION;
D O I
10.1080/19466315.2019.1610043
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article deals with comparing a test with a control therapy using meta-analyses of data from randomized controlled trials with a time-to-event endpoint. Such analyses can often benefit from prior information about the distribution of control group outcomes. One possible source of this information is the published aggregate data about control groups of historical trials from the medical literature. We review methods for making posterior inference about exponentially distributed event times more robust to prior-data conflicts by discounting the prior information based on the extent of observed prior-data conflict. We use simulations to compare analyses without prior information with the meta-analytic combined, meta-analytic predictive and robust meta-analytic predictive approaches, as well as Bayesian model averaging using shrinkage priors. Bayesian model averaging via shrinkage priors with well-chosen hyperpriors performed best in terms of credible interval coverage and mean-squared error across scenarios. For the robust meta-analytic predictive approach, there was little benefit in increasing the weight of the informative mixture components beyond 0.2-0.5. This was the case even when little prior-data conflict was expected, except with very sparse data or substantial between-trial heterogeneity in control group hazard rates. for this article are available online.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 50 条
  • [21] Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
    Li, Yimei
    Hwang, Wei-Ting
    Maude, Shannon L.
    Teachey, David T.
    Frey, Noelle V.
    Myers, Regina M.
    Leahy, Allison Barz
    Liu, Hongyan
    Porter, David L.
    Grupp, Stephan A.
    Shaw, Pamela A.
    CLINICAL CANCER RESEARCH, 2022, 28 (18) : 3940 - 3949
  • [22] Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
    Wang, Shuai
    Frederich, Robert
    Mancuso, James P.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (01) : 114 - 126
  • [23] Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review
    Grady, Connor B.
    Li, Yimei
    Maude, Shannon L.
    Hexner, Elizabeth O.
    Frey, Noelle, V
    Porter, David L.
    Hwang, Wei-Ting
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (04): : 271e1 - 271e13
  • [24] Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials
    Renfro, Lindsay A.
    Shi, Qian
    Sargent, Daniel J.
    Carlin, Bradley P.
    STATISTICS IN MEDICINE, 2012, 31 (08) : 743 - 761
  • [25] The value of the aggregate data approach in meta-analysis with time-to-event outcomes
    Tudur, C
    Williamson, PR
    Khan, S
    Best, LY
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2001, 164 : 357 - 370
  • [26] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
    Eliana Rulli
    Francesca Ghilotti
    Elena Biagioli
    Luca Porcu
    Mirko Marabese
    Maurizio D’Incalci
    Rino Bellocco
    Valter Torri
    British Journal of Cancer, 2018, 119 : 1456 - 1463
  • [27] Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints
    Cotterill, Amy
    Whitehead, John
    STATISTICS IN MEDICINE, 2015, 34 (11) : 1889 - 1903
  • [28] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
    Rulli, Eliana
    Ghilotti, Francesca
    Biagioli, Elena
    Porcu, Luca
    Marabese, Mirko
    D'Incalci, Maurizio
    Bellocco, Rino
    Torri, Valter
    BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1456 - 1463
  • [29] Investigations of methods for multiple time-to-event endpoints: A chronic myeloid leukemia data analysis
    Wu, Hongji
    Hou, Yawen
    Chen, Zheng
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2023, 29 (01) : 211 - 217
  • [30] Bayesian design of clinical trials using joint models for longitudinal and time-to-event data
    Xu, Jiawei
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    BIOSTATISTICS, 2022, 23 (02) : 591 - 608